{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:05:05Z","timestamp":1785899105083,"version":"3.56.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02668-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T10:42:51Z","timestamp":1752921771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-density lipoprotein cholesterol, particles and subspecies and the risk of chronic kidney disease: The PREVEND prospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Setor K.","family":"Kunutsor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"12","key":"2668_CR1","first-page":"7","volume":"2022","author":"CP Kovesdy","year":"2011","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2011;2022(12):7\u201311.","journal-title":"Kidney Int Suppl"},{"key":"2668_CR2","unstructured":"World Health Organization. Fact sheets. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-deathRetrieved on 10 Sep 2021."},{"key":"2668_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ki.2011.368","volume":"80","author":"WG Couser","year":"2011","unstructured":"Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258\u201370.","journal-title":"Kidney Int"},{"key":"2668_CR4","unstructured":"CDC. Risk Factors for Chronic Kidney Disease (2024). https:\/\/www.cdc.gov\/kidney-disease\/risk-factors\/index.html. Accessed on January 03, 2024."},{"key":"2668_CR5","first-page":"1158","volume":"37","author":"K Lyu","year":"2024","unstructured":"Lyu K, Liu S, Liu Y, You J, Wang X, Jiang M, Yin C, Zhang D, Bai Y, Wang M, Zheng S. The Effect of Blood Lipid Profiles on Chronic Kidney Disease in a Prospective Cohort: Based on a Regression Discontinuity Design. Biomed Environ Sci. 2024;37:1158\u201372.","journal-title":"Biomed Environ Sci"},{"key":"2668_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneph.2009.184","volume":"5","author":"XZ Ruan","year":"2009","unstructured":"Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713\u201321.","journal-title":"Nat Rev Nephrol"},{"key":"2668_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","volume":"58","author":"P Muntner","year":"2000","unstructured":"Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293\u2013301.","journal-title":"Kidney Int"},{"key":"2668_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2020.03.020","volume":"300","author":"YB Zhang","year":"2020","unstructured":"Zhang YB, Sheng LT, Wei W, Guo H, Yang H, Min X, Guo K, Yang K, Zhang X, He M, et al. Association of blood lipid profile with incident chronic kidney disease: A Mendelian randomization study. Atherosclerosis. 2020;300:19\u201325.","journal-title":"Atherosclerosis"},{"key":"2668_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12882-020-01907-5","volume":"21","author":"X Liang","year":"2020","unstructured":"Liang X, Ye M, Tao M, Zheng D, Cai R, Zhu Y, Jin J, He Q. The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: a retrospective study. BMC Nephrol. 2020;21:252.","journal-title":"BMC Nephrol"},{"key":"2668_CR10","doi-asserted-by":"publisher","first-page":"1190938","DOI":"10.3389\/fimmu.2023.1190938","volume":"14","author":"C Hu","year":"2023","unstructured":"Hu C, Li Y, Qian Y, Wu Z, Hu B, Peng Z. Kidney function and cardiovascular diseases: a large-scale observational and Mendelian randomization study. Front Immunol. 2023;14:1190938.","journal-title":"Front Immunol"},{"key":"2668_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1161\/CIRCULATIONAHA.122.060700","volume":"146","author":"L Gaziano","year":"2022","unstructured":"Gaziano L, Sun L, Arnold M, Bell S, Cho K, Kaptoge SK, Song RJ, Burgess S, Posner DC, Mosconi K, et al. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. Circulation. 2022;146:1507\u201317.","journal-title":"Circulation"},{"key":"2668_CR12","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935\u201359.","journal-title":"J Am Coll Cardiol"},{"key":"2668_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","volume":"7","author":"PP Toth","year":"2013","unstructured":"Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D\u2019Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:484\u2013525.","journal-title":"J Clin Lipidol"},{"key":"2668_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/eurjpc\/zwac272","volume":"30","author":"SK Kunutsor","year":"2023","unstructured":"Kunutsor SK, Laukkanen JA. Further proof of a paradoxical relationship between high-density lipoprotein levels and adverse cardiovascular outcomes: are there implications for cardiovascular disease prevention? Eur J Prev Cardiol. 2023;30:290\u20132.","journal-title":"Eur J Prev Cardiol"},{"key":"2668_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2217\/bmm.13.35","volume":"7","author":"M Triolo","year":"2013","unstructured":"Triolo M, Annema W, Dullaart RP, Tietge UJ. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med. 2013;7:457\u201372.","journal-title":"Biomark Med"},{"key":"2668_CR16","doi-asserted-by":"crossref","unstructured":"Corsetti JP, Bakker SJL, Gansevoort RT, Gruppen EG, Connelly MA, Sparks CE, Dullaart RPF: Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk. Int J Mol Sci 2019;20.","DOI":"10.3390\/ijms20040977"},{"key":"2668_CR17","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478\u201386.","journal-title":"Eur Heart J"},{"key":"2668_CR18","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2215\/CJN.00730116","volume":"11","author":"B Bowe","year":"2016","unstructured":"Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed MA, Al-Aly Z. High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clin J Am Soc Nephrol. 2016;11:1784\u20131793.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2668_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2362.2010.02287.x","volume":"40","author":"JP Corsetti","year":"2010","unstructured":"Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RP. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest. 2010;40:483\u20139.","journal-title":"Eur J Clin Invest"},{"key":"2668_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","volume":"51","author":"WA van der Steeg","year":"2008","unstructured":"van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"2668_CR21","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1194\/jlr.R035725","volume":"54","author":"AS Shah","year":"2013","unstructured":"Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res. 2013;54:2575\u201385.","journal-title":"J Lipid Res"},{"key":"2668_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clinbiochem.2014.11.017","volume":"48","author":"SP Matyus","year":"2015","unstructured":"Matyus SP, Braun PJ, Wolak-Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, Warner SM, Fischer TJ, Connelly MA. HDL particle number measured on the Vantera(R), the first clinical NMR analyzer. Clin Biochem. 2015;48:148\u201355.","journal-title":"Clin Biochem"},{"key":"2668_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14797\/mdcj-15-1-55","volume":"15","author":"WS Davidson","year":"2019","unstructured":"Davidson WS, Shah AS. High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes. Methodist Debakey Cardiovasc J. 2019;15:55\u201361.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2668_CR24","doi-asserted-by":"crossref","unstructured":"Sokooti S, Szili-Torok T, Flores-Guerrero JL, Oste MCJ, Gomes-Neto AW, Kootstra-Ros JE, Heerspink HJL, Connelly MA, Bakker SJL, Dullaart RPF. High-Density Lipoprotein Particles and Their Relationship to Posttransplantation Diabetes Mellitus in Renal Transplant Recipients. Biomolecules. 2020;10.","DOI":"10.3390\/biom10030481"},{"key":"2668_CR25","doi-asserted-by":"publisher","first-page":"e031160","DOI":"10.1161\/JAHA.123.031160","volume":"12","author":"A Deets","year":"2023","unstructured":"Deets A, Joshi PH, Chandra A, Singh K, Khera A, Virani SS, Ballantyne CM, Otvos JD, Dullaart RPF, Gruppen EG, et al. Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023;12:e031160.","journal-title":"J Am Heart Assoc"},{"key":"2668_CR26","doi-asserted-by":"crossref","unstructured":"Kunutsor SK, Bhattacharjee A, Connelly MA, Bakker SJL, Dullaart RPF. Alcohol Consumption, High-Density Lipoprotein Particles and Subspecies, and Risk of Cardiovascular Disease: Findings from the PREVEND Prospective Study. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25042290"},{"key":"2668_CR27","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1210\/clinem\/dgab075","volume":"106","author":"S Sokooti","year":"2021","unstructured":"Sokooti S, Flores-Guerrero JL, Kieneker LM, Heerspink HJL, Connelly MA, Bakker SJL, Dullaart RPF. HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study. J Clin Endocrinol Metab. 2021;106:1761\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"2668_CR28","doi-asserted-by":"crossref","unstructured":"Kosugi T, Eriguchi M, Yoshida H, Tamaki H, Uemura T, Tasaki H, Furuyama R, Fukata F, Nishimoto M, Matsui M, et al: Serum High-Density Lipoprotein Cholesterol Levels and the Risk of Kidney Function Decline: The Japan Specific Health Checkups (J\u2011SHC) Study. J Atheroscler Thromb 2024.","DOI":"10.5551\/jat.65107"},{"key":"2668_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.kint.2015.12.034","volume":"89","author":"B Bowe","year":"2016","unstructured":"Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89:886\u201396.","journal-title":"Kidney Int"},{"key":"2668_CR30","doi-asserted-by":"publisher","first-page":"e011162","DOI":"10.1161\/JAHA.118.011162","volume":"8","author":"KH Nam","year":"2019","unstructured":"Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, Yun HR, Park JT, Yoo TH, Sung SA, et al. Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD. J Am Heart Assoc. 2019;8:e011162.","journal-title":"J Am Heart Assoc"},{"key":"2668_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0022-2275(20)41437-3","volume":"33","author":"M Hannuksela","year":"1992","unstructured":"Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res. 1992;33:737\u201344.","journal-title":"J Lipid Res"},{"key":"2668_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/ajcn\/nqy217","volume":"108","author":"EG Gruppen","year":"2018","unstructured":"Gruppen EG, Bakker SJL, James RW, Dullaart RPF. Serum paraoxonase-1 activity is associated with light to moderate alcohol consumption: the PREVEND cohort study. Am J Clin Nutr. 2018;108:1283\u201390.","journal-title":"Am J Clin Nutr"},{"key":"2668_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00041433-200102000-00004","volume":"12","author":"A van Tol","year":"2001","unstructured":"van Tol A, Hendriks HF. Moderate alcohol consumption: effects on lipids and cardiovascular disease risk. Curr Opin Lipidol. 2001;12:19\u201323.","journal-title":"Curr Opin Lipidol"},{"key":"2668_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MOL.0b013e32833c1f41","volume":"21","author":"EA Brinton","year":"2010","unstructured":"Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. 2010;21:346\u201351.","journal-title":"Curr Opin Lipidol"},{"key":"2668_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/vhrm.2006.2.3.239","volume":"2","author":"JR Emberson","year":"2006","unstructured":"Emberson JR, Bennett DA. Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both? Vasc Health Risk Manag. 2006;2:239\u201349.","journal-title":"Vasc Health Risk Manag"},{"key":"2668_CR36","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.12659\/MSM.916121","volume":"25","author":"Z Fan","year":"2019","unstructured":"Fan Z, Yun J, Yu S, Yang Q, Song L. Alcohol Consumption Can be a \u201cDouble-Edged Sword\u201d for Chronic Kidney Disease Patients. Med Sci Monit. 2019;25:7059\u201372.","journal-title":"Med Sci Monit"},{"key":"2668_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2668_CR38","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/aje\/kwn209","volume":"168","author":"Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT, Group PS","year":"2008","unstructured":"Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT, Group PS. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol. 2008;168:897\u2013905.","journal-title":"Am J Epidemiol"},{"key":"2668_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.atherosclerosis.2014.12.045","volume":"238","author":"SK Kunutsor","year":"2014","unstructured":"Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis. 2014;238:356\u201364.","journal-title":"Atherosclerosis"},{"key":"2668_CR40","doi-asserted-by":"publisher","first-page":"e006503","DOI":"10.1161\/JAHA.117.006503","volume":"6","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Kieneker LM, Burgess S, Bakker SJL, Dullaart RPF. Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach. J Am Heart Assoc. 2017;6:e006503.","journal-title":"J Am Heart Assoc"},{"key":"2668_CR41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/ATVBAHA.114.304929","volume":"35","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35:716\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2668_CR42","doi-asserted-by":"crossref","unstructured":"Kunutsor SK, Kieneker LM, Burgess S, Bakker SJL, Dullaart RPF: Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach. J Am Heart Assoc 2017;6.","DOI":"10.1161\/JAHA.117.006503"},{"key":"2668_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2021.05.024","volume":"520","author":"SK Kunutsor","year":"2021","unstructured":"Kunutsor SK, Kremer D, Eisenga MF, Gruppen EG, de Borst MH, Muller Kobold AC, Kootstra-Ros JE, Dullaart RPF, Bakker SJL. Self-reported alcohol consumption, carbohydrate deficient transferrin and risk of cardiovascular disease: The PREVEND prospective cohort study. Clin Chim Acta. 2021;520:1\u20137.","journal-title":"Clin Chim Acta"},{"key":"2668_CR44","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehm062","volume":"28","author":"Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BH, Grobbee DE, van Tol A, Dullaart RP, Group PS","year":"2007","unstructured":"Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BH, Grobbee DE, van Tol A, Dullaart RP, Group PS. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J. 2007;28:1012\u20138.","journal-title":"Eur Heart J"},{"key":"2668_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.atherosclerosis.2009.07.042","volume":"208","author":"Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ, Group PS","year":"2010","unstructured":"Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ, Group PS. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis. 2010;208:537\u201342.","journal-title":"Atherosclerosis"},{"key":"2668_CR46","doi-asserted-by":"publisher","first-page":"e39110","DOI":"10.1371\/journal.pone.0039110","volume":"7","author":"JP Corsetti","year":"2012","unstructured":"Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS ONE. 2012;7:e39110.","journal-title":"PLoS ONE"},{"key":"2668_CR47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.09.006","volume":"243","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Blokzijl H, Gansevoort RT, Dullaart RP. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study. Atherosclerosis. 2015;243:138\u201347.","journal-title":"Atherosclerosis"},{"key":"2668_CR48","doi-asserted-by":"publisher","first-page":"e0132822","DOI":"10.1371\/journal.pone.0132822","volume":"10","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Gregson J, Dullaart RP. Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein. PLoS ONE. 2015;10:e0132822.","journal-title":"PLoS ONE"},{"key":"2668_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20\u20139.","journal-title":"N Engl J Med"},{"key":"2668_CR50","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/ndt\/gfae054","volume":"39","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Dey RS, Touw DJ, Bakker SJL, Dullaart RPF. Urine cotinine versus self-reported smoking and the risk of chronic kidney disease. Nephrol Dial Transplant. 2024;39:1683\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"2668_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000."},{"key":"2668_CR52","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/ndt\/gfy361","volume":"35","author":"CHL Thio","year":"2020","unstructured":"Thio CHL, Vart P, Kieneker LM, Snieder H, Gansevoort RT, Bultmann U. Educational level and risk of chronic kidney disease: longitudinal data from the PREVEND study. Nephrol Dial Transplant. 2020;35:1211\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2668_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10654-011-9606-1","volume":"26","author":"RH Groenwold","year":"2011","unstructured":"Groenwold RH, Klungel OH, Grobbee DE, Hoes AW. Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol. 2011;26:589\u201393.","journal-title":"Eur J Epidemiol"},{"key":"2668_CR54","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.120.045713","volume":"142","author":"K Singh","year":"2020","unstructured":"Singh K, Chandra A, Sperry T, Joshi PH, Khera A, Virani SS, Ballantyne CM, Otvos JD, Dullaart RPF, Gruppen EG, et al. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020;142:657\u201369.","journal-title":"Circulation"},{"key":"2668_CR55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.jrn.2019.01.011","volume":"30","author":"EA Hu","year":"2020","unstructured":"Hu EA, Lazo M, Rosenberg SD, Grams ME, Steffen LM, Coresh J, Rebholz CM. Alcohol Consumption and Incident Kidney Disease: Results From the Atherosclerosis Risk in Communities Study. J Ren Nutr. 2020;30:22\u201330.","journal-title":"J Ren Nutr"},{"key":"2668_CR56","doi-asserted-by":"publisher","first-page":"e0203410","DOI":"10.1371\/journal.pone.0203410","volume":"13","author":"CS Pan","year":"2018","unstructured":"Pan CS, Ju TR, Lee CC, Chen YP, Hsu CY, Hung DZ, Chen WK, Wang IK. Alcohol use disorder tied to development of chronic kidney disease: A nationwide database analysis. PLoS ONE. 2018;13:e0203410.","journal-title":"PLoS ONE"},{"key":"2668_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcvm.2020.00039","volume":"7","author":"A Jomard","year":"2020","unstructured":"Jomard A, Osto E. High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. Front Cardiovasc Med. 2020;7:39.","journal-title":"Front Cardiovasc Med"},{"key":"2668_CR58","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1093\/eurheartj\/ehx274","volume":"38","author":"PJ Barter","year":"2017","unstructured":"Barter PJ, Rye KA. HDL cholesterol concentration or HDL function: which matters? Eur Heart J. 2017;38:2487\u20139.","journal-title":"Eur Heart J"},{"key":"2668_CR59","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1161\/CIRCULATIONAHA.120.050808","volume":"143","author":"C Jia","year":"2021","unstructured":"Jia C, Anderson JLC, Gruppen EG, Lei Y, Bakker SJL, Dullaart RPF, Tietge UJF. High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. Circulation. 2021;143:1935\u201345.","journal-title":"Circulation"},{"key":"2668_CR60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/bph.12174","volume":"169","author":"A Tran-Dinh","year":"2013","unstructured":"Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Lapergue B, Burillo E, Michel JB, Levoye A, Martin-Ventura JL, Meilhac O. HDL and endothelial protection. Br J Pharmacol. 2013;169:493\u2013511.","journal-title":"Br J Pharmacol"},{"key":"2668_CR61","doi-asserted-by":"crossref","unstructured":"Robert J, Osto E, von Eckardstein A: The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions. Cells 2021;10.","DOI":"10.3390\/cells10051041"},{"key":"2668_CR62","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0306-3623(98)00028-7","volume":"31","author":"B Mackness","year":"1998","unstructured":"Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31:329\u201336.","journal-title":"Gen Pharmacol"},{"key":"2668_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","volume":"21","author":"A Kontush","year":"2010","unstructured":"Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010;21:312\u20138.","journal-title":"Curr Opin Lipidol"},{"key":"2668_CR64","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2337\/dc14-0645","volume":"38","author":"RH Mackey","year":"2015","unstructured":"Mackey RH, Mora S, Bertoni AG, Wassel CL, Carnethon MR, Sibley CT, Goff DC Jr. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 2015;38:628\u201336.","journal-title":"Diabetes Care"},{"key":"2668_CR65","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12882-024-03808-3","volume":"25","author":"Z Xu","year":"2024","unstructured":"Xu Z, Yang S, Cui L. Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews. BMC Nephrol. 2024;25:400.","journal-title":"BMC Nephrol"},{"key":"2668_CR66","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1210\/jc.2010-2061","volume":"96","author":"X Wang","year":"2011","unstructured":"Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it\u2019s not just about sex hormones. J Clin Endocrinol Metab. 2011;96:885\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2668_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00043798-200304000-00010","volume":"10","author":"S Lewington","year":"2003","unstructured":"Lewington S, Thomsen T, Davidsen M, Sherliker P, Clarke R. Regression dilution bias in blood total and high-density lipoprotein cholesterol and blood pressure in the Glostrup and Framingham prospective studies. J Cardiovasc Risk. 2003;10:143\u20138.","journal-title":"J Cardiovasc Risk"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02668-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:45:18Z","timestamp":1757259918000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02668-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02668-6","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this investigation involving human participants were approved by the Medical Ethics Committee of the University Medical Center Groningen (Reference: MEC 96\/01\/022). Written informed consent was obtained from all the participants. The study design was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Margery A. Connelly is an employee of and holds stock in Labcorp. All other authors report no relationships that could be construed as a conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}